Biomm

Biomm Fixed Asset Turnover

The Fixed Asset Turnover of Biomm (BIOM3.SA) as of Nov 7, 2026 is 1.64. In the previous year, Fixed Asset Turnover was 0.85 — a change of 92.86% (higher).

Fixed Asset Turnover

1.64

YoY

92.86%

Last updated:

Fixed Asset Turnover of Biomm is 2025 1.64 . Fixed Asset Turnover of Biomm was 2024 0.85 . It decreases by 92.86% higher compared to the previous year.

The Biomm Fixed Asset Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Fixed Asset Turnover
Date
Fixed Asset Turnover
Jan 1, 2018
0.01 BRL
Jan 1, 2019
0.06 BRL
Jan 1, 2020
0.37 BRL
Jan 1, 2021
0.66 BRL
Jan 1, 2022
0.64 BRL
Jan 1, 2023
0.71 BRL
Jan 1, 2024
0.85 BRL
Jan 1, 2025
1.64 BRL
The Biomm Fixed Asset Turnover history
YEARFixed Asset TurnoverYoY
1.64+92.86%
0.85+19.53%
0.71+11.27%
0.64-2.34%
0.66+78.75%
0.37+563.45%
0.06+452.21%
0.01+1,414.52%
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

Fixed Asset Turnover of Biomm is 1.64 in 2025.

Fixed Asset Turnover of Biomm changed from 0.85 to 1.64, representing a 92.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Fixed Asset Turnover Biomm since 2006 – with annual values, charts, and detailed analysis.

Fixed asset turnover measures revenue generated per unit of PP&E. Higher ratios indicate more efficient utilization of physical assets.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Fixed Asset Turnover's Biomm with sector peers and the industry average to assess whether it is attractive.

To evaluate Fixed Asset Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Fixed Asset Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biomm

All Key Metrics — Biomm